SR 18292 – 5 mg

Brand:
Cayman
CAS:
2095432-55-4
Storage:
-20
UN-No:
Non-Hazardous - /

SR 18292 is an inhibitor of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), a coactivator of transcription factors for genes involved in gluconeogenesis.{37125} SR 18292 (20 µM) increases acetylation of PGC-1α and, subsequently, decreases mRNA expression of phosphoenolpyruvate carboxykinase 1 (PEPCK1/Pck1) and the glucose-6-phosphatase catalytic subunit (G6Pc) in primary hepatocytes following stimulation with glucagon. In a dietary model of type II diabetes mellitus in mice, SR 18292 (45 mg/kg, i.p., for four days) reduces fasting blood glucose levels and the expression of liver Pck1. It also enhances glucose tolerance and insulin sensitivity in two mouse models of obesity.  

 

Out of stock

SKU: 22084 - Category:

Description

An inhibitor of PGC-1α, increases acetylation of PGC-1α; decreases mRNA expression of Pck1 and G6Pc in primary hepatocytes following glucagon stimulation; reduces fasting blood glucose and Pck1 expression in the liver in a dietary model of type II diabetes in mice at a dose of 45 mg/kg, i.p, for four days; enhances glucose tolerance and insulin sensitivity in two mouse models of obesity


Formal name: 1-[(1,1-dimethylethyl)[(4-methylphenyl)methyl]amino]-3-(1H-indol-4-yloxy)-2-propanol

Synonyms: 

Molecular weight: 366.5

CAS: 2095432-55-4

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Endocrinology & Metabolism|Carbohydrate Metabolism||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity